MXPA02009603A - Terapias de dosis divididas con actividad de deterioro vascular. - Google Patents
Terapias de dosis divididas con actividad de deterioro vascular.Info
- Publication number
- MXPA02009603A MXPA02009603A MXPA02009603A MXPA02009603A MXPA02009603A MX PA02009603 A MXPA02009603 A MX PA02009603A MX PA02009603 A MXPA02009603 A MX PA02009603A MX PA02009603 A MXPA02009603 A MX PA02009603A MX PA02009603 A MXPA02009603 A MX PA02009603A
- Authority
- MX
- Mexico
- Prior art keywords
- vascular damaging
- divided dose
- damaging activity
- dose therapies
- damaging agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
La invencion se refiere al uso de un agente de deterioro vascular o una sal farmaceuticamente aceptable del mismo, en la fabricacion de un medicamento para la administracion en dosis divididas para utilizarse en la produccion de un efecto de deterioro vascular en un animal de sangre caliente tal como un humano. En particular, el agente de deterioro vascular es ZD6126, o una sal farmaceuticamente aceptable del mismo. La invencion tambien se refiere a los metodos de tratamiento que utilizan un agente de deterioro vascular en dosis divididas.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0007740A GB0007740D0 (en) | 2000-03-31 | 2000-03-31 | Combination therapy |
| GB0013928A GB0013928D0 (en) | 2000-06-08 | 2000-06-08 | Methods of treatment |
| GB0014904A GB0014904D0 (en) | 2000-06-20 | 2000-06-20 | Methods of treatment |
| PCT/GB2001/001329 WO2001074369A1 (en) | 2000-03-31 | 2001-03-27 | Divided dose therapies with vascular damaging activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA02009603A true MXPA02009603A (es) | 2004-05-14 |
Family
ID=27255635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA02009603A MXPA02009603A (es) | 2000-03-31 | 2001-03-27 | Terapias de dosis divididas con actividad de deterioro vascular. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20030055024A1 (es) |
| EP (1) | EP1272200B1 (es) |
| JP (1) | JP2003528921A (es) |
| KR (1) | KR20020084267A (es) |
| CN (1) | CN1422157A (es) |
| AT (1) | ATE298240T1 (es) |
| AU (2) | AU2001242586B2 (es) |
| BR (1) | BR0109671A (es) |
| CA (1) | CA2402078A1 (es) |
| CZ (1) | CZ20023231A3 (es) |
| DE (1) | DE60111622T2 (es) |
| EE (1) | EE200200549A (es) |
| ES (1) | ES2243466T3 (es) |
| HU (1) | HUP0300576A3 (es) |
| IL (1) | IL151627A0 (es) |
| IS (1) | IS6555A (es) |
| MX (1) | MXPA02009603A (es) |
| NO (1) | NO20024683L (es) |
| NZ (1) | NZ534190A (es) |
| PL (1) | PL357282A1 (es) |
| PT (1) | PT1272200E (es) |
| SK (1) | SK13902002A3 (es) |
| WO (1) | WO2001074369A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE200200565A (et) * | 2000-03-31 | 2004-06-15 | Angiogene Pharmaceuticals Ltd. | Vaskulaarse kahjustava toimega kombinatsioonravi |
| US20040067255A1 (en) * | 2002-10-07 | 2004-04-08 | Chaplin David J. | Method of administering split doses of a vascular targeting agent |
| GB0223379D0 (en) * | 2002-10-09 | 2002-11-13 | Angiogene Pharm Ltd | Combination therapy |
| FR2848212B1 (fr) * | 2002-12-06 | 2006-10-27 | Aventis Pharma Sa | Derives de la colchicine, procede de preparation, produits obtenus par ce procede et utilisation |
| KR20060036058A (ko) * | 2003-06-18 | 2006-04-27 | 앤지오젠 파마슈티칼스 리미티드 | 결장직장암의 치료를 위한 혈관 손상 활성을 갖는 5ｆｕ,ｃｐｔ-11 또는 5-ｆｕ 및 ｃｐｔ-11과 함께 ｚｄ6126을포함하는 조성물 |
| GB0316127D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
| GB0316123D0 (en) * | 2003-07-10 | 2003-08-13 | Astrazeneca Ab | Combination therapy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI830078L (fi) * | 1982-01-15 | 1983-07-16 | Lilly Co Eli | Askorbinsyraetrar och liknande foereningar |
| US4996237A (en) * | 1987-01-06 | 1991-02-26 | Arizona Board Of Regents | Combretastatin A-4 |
| AU6605690A (en) * | 1989-10-27 | 1991-05-31 | Du Pont Merck Pharmaceutical Company, The | Monoclonal antibodies to basic fibroblast growth factor that inhibit its biological activity |
| WO1991015495A1 (en) * | 1990-04-02 | 1991-10-17 | Pfizer Inc. | Benzylphosphonic acid tyrosine kinase inhibitors |
| CA2108889A1 (en) * | 1991-05-29 | 1992-11-30 | Robert Lee Dow | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
| US5561122A (en) * | 1994-12-22 | 1996-10-01 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Combretastatin A-4 prodrug |
| GB9714249D0 (en) * | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| JPH11228594A (ja) * | 1998-02-16 | 1999-08-24 | Meiji Milk Prod Co Ltd | 新規プロゲステロン化合物 |
| AU5717400A (en) * | 1999-06-14 | 2001-01-02 | Cancer Research Ventures Limited | Cancer therapy |
| US20040067255A1 (en) * | 2002-10-07 | 2004-04-08 | Chaplin David J. | Method of administering split doses of a vascular targeting agent |
-
2001
- 2001-03-27 EP EP01915495A patent/EP1272200B1/en not_active Expired - Lifetime
- 2001-03-27 AT AT01915495T patent/ATE298240T1/de not_active IP Right Cessation
- 2001-03-27 BR BR0109671-0A patent/BR0109671A/pt not_active IP Right Cessation
- 2001-03-27 CN CN01807663A patent/CN1422157A/zh active Pending
- 2001-03-27 HU HU0300576A patent/HUP0300576A3/hu unknown
- 2001-03-27 PT PT01915495T patent/PT1272200E/pt unknown
- 2001-03-27 WO PCT/GB2001/001329 patent/WO2001074369A1/en not_active Application Discontinuation
- 2001-03-27 DE DE60111622T patent/DE60111622T2/de not_active Expired - Fee Related
- 2001-03-27 SK SK1390-2002A patent/SK13902002A3/sk unknown
- 2001-03-27 US US10/239,898 patent/US20030055024A1/en not_active Abandoned
- 2001-03-27 CA CA002402078A patent/CA2402078A1/en not_active Abandoned
- 2001-03-27 EE EEP200200549A patent/EE200200549A/xx unknown
- 2001-03-27 CZ CZ20023231A patent/CZ20023231A3/cs unknown
- 2001-03-27 ES ES01915495T patent/ES2243466T3/es not_active Expired - Lifetime
- 2001-03-27 PL PL01357282A patent/PL357282A1/xx not_active Application Discontinuation
- 2001-03-27 KR KR1020027012915A patent/KR20020084267A/ko not_active Application Discontinuation
- 2001-03-27 AU AU2001242586A patent/AU2001242586B2/en not_active Ceased
- 2001-03-27 IL IL15162701A patent/IL151627A0/xx unknown
- 2001-03-27 AU AU4258601A patent/AU4258601A/xx active Pending
- 2001-03-27 NZ NZ534190A patent/NZ534190A/en unknown
- 2001-03-27 MX MXPA02009603A patent/MXPA02009603A/es unknown
- 2001-03-27 JP JP2001572112A patent/JP2003528921A/ja active Pending
-
2002
- 2002-09-19 IS IS6555A patent/IS6555A/is unknown
- 2002-09-30 NO NO20024683A patent/NO20024683L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL357282A1 (en) | 2004-07-26 |
| IL151627A0 (en) | 2003-04-10 |
| IS6555A (is) | 2002-10-18 |
| WO2001074369A1 (en) | 2001-10-11 |
| EE200200549A (et) | 2004-02-16 |
| ES2243466T3 (es) | 2005-12-01 |
| EP1272200B1 (en) | 2005-06-22 |
| DE60111622D1 (de) | 2005-07-28 |
| HUP0300576A2 (hu) | 2003-07-28 |
| NO20024683L (no) | 2002-10-15 |
| HUP0300576A3 (en) | 2005-02-28 |
| AU2001242586B2 (en) | 2004-12-16 |
| JP2003528921A (ja) | 2003-09-30 |
| KR20020084267A (ko) | 2002-11-04 |
| AU4258601A (en) | 2001-10-15 |
| CZ20023231A3 (cs) | 2003-01-15 |
| CA2402078A1 (en) | 2001-10-11 |
| EP1272200A1 (en) | 2003-01-08 |
| ATE298240T1 (de) | 2005-07-15 |
| BR0109671A (pt) | 2003-02-04 |
| NZ534190A (en) | 2007-05-31 |
| US20030055024A1 (en) | 2003-03-20 |
| DE60111622T2 (de) | 2006-05-18 |
| SK13902002A3 (sk) | 2003-05-02 |
| NO20024683D0 (no) | 2002-09-30 |
| CN1422157A (zh) | 2003-06-04 |
| PT1272200E (pt) | 2005-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG169233A1 (en) | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation | |
| PT1326613E (pt) | Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos | |
| NO20014519D0 (no) | Apomorfin- og sildenafilpreparat | |
| SG167657A1 (en) | Novel medicament compositions based on tiotropium salts and on salmeterol salts | |
| GB9814172D0 (en) | Formulation for inhalation | |
| WO2004045593A3 (en) | Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy | |
| HK1130422A1 (en) | A new use of deferiprone | |
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| NZ517038A (en) | Use of serotonin reuptake inihibitor in medicaments for treating sexual dysfunction | |
| AU4258101A (en) | Combination therapies with vascular damaging activity | |
| NZ507203A (en) | Use of dexmedetomidine for ICU sedation | |
| MXPA02009603A (es) | Terapias de dosis divididas con actividad de deterioro vascular. | |
| NZ534221A (en) | A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction | |
| CA2516458A1 (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| IL159770A0 (en) | Calcium salts with cytotoxic activity | |
| CA2515259A1 (en) | Use of acetylsalicylic acid for the treatment of hemorrhoidal disease | |
| RU2002129097A (ru) | Комбинированные терапии с использованием активности, повреждающей сосуды | |
| SE0000837D0 (sv) | New use | |
| IL164092A0 (en) | The use of devazepide as analgesic agent |